WHO’s New Essential Medicines List: CEO Of Patients’ Alliance Shares Views 10/07/2019 Guest contributor Kawaldip Sehmi, CEO of the International Alliance of Patients’ Organizations (IAPO), answers 5 questions on why the Essential Medicines List is important for patients. IAPO is a United Kingdom-based alliance of 276 member organisations from 71 countries representing 50 disease areas, and working in collaboration with civil society, UN agencies and the healthcare industry. Sehmi holds a […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Text Of Italian Transparency Proposal Shows North-South Divide Emerging 08/05/2019 David Branigan A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts